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Abstract
Sex and gender differences influence the health and wellbeing of men and women. Although studies have drawn
attention to observed differences between women and men across diseases, remarkably little research has been
pursued to systematically investigate these underlying sex differences. Women continue to be underrepresented in
clinical trials, and even in studies in which both men and women participate, systematic analysis of data to identify
potential sex-based differences is lacking. Standards for reporting of clinical trials have been established to ensure
provision of complete, transparent and critical information. An important step in addressing the gender imbalance
would be inclusion of a gender perspective in the next Consolidated Standards of Reporting Trials (CONSORT)
guideline revision. Uniform Requirements for Manuscripts Submitted to Biomedical Journals, as a set of well-
recognized and widely used guidelines for authors and biomedical journals, should similarly emphasize the ethical
obligation of authors to present data analyzed by gender as a matter of routine. Journal editors are also promoters
of ethical research and adequate standards of reporting, and requirements for inclusion of gender analyses should
be integrated into editorial policies as a matter of urgency.
Main text
A person’s sex is an important health determinant. In a
variety of instances, it has been shown that physiological
differences between the sexes influence health outcomes.
Genetic differences translate into distinct anatomy,
result in variations in hormone production, and affect
immunological and inflammatory responses. Ultimately,
these multiple factors influence the health and wellbeing
of men and women, explaining the diverse demo-
graphics and epidemiology of diseases, as well as distinc-
tive responses to illness. In addition, there is a complex
interplay between innate physiological sex differences
and socioeconomic and behavioural gender differences
that further affect health outcomes.
Although studies have drawn attention to observed
differences between women and men across diseases,
few have been designed to specifically do so. Some of
these patterns have been observed as early as during
foetal development, where external influence is
minimized. For example, female infants may be at a sub-
stantially higher risk of acquiring HIV in utero than
male infants, even after adjusting for confounders such
as mothers’ viral load and birth weight [1], and male
infants seem more likely to be infected during breast
feeding [2].
Similarly, women and men have been shown to dis-
play disparate immunity and immunopathology in
response to a series of microbial infections, indicating a
complex interaction between microbe-specific and gen-
der-specific immune responses [3]. Autoimmune dis-
eases, such as Systemic Lupus Erythematosus and
rheumatoid arthritis, are more prevalent in women than
men, and women more frequently reject allogeneic
grafts after cardiac transplantation, with higher post-
operative mortality [4]. A set of gender differences has
also been observed in chronic pain, with some condi-
tions further influenced differentially by age [5].
Remarkably little research has been pursued to sys-
tematically investigate these underlying sex differences.
For too long, medical research has turned a blind eye to
differences in disease prevalence, progression and clini-
cal outcomes between women and men. Women
* Correspondence: shirin.heidari@iasociety.org
† Contributed equally
1International AIDS Society, Geneva, Switzerland
Full list of author information is available at the end of the article
Heidari et al. Journal of the International AIDS Society 2012, 15:11
http://www.jiasociety.org/content/15/1/11
© 2012 Heidari et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
continue to be underrepresented in clinical trials and
are subject to medical practices based on data from a
predominantly Caucasian male population [6]. Some
would even argue that medicine as it is practiced today
is less evidence-based for women than it is for men.
Even in studies in which both men and women parti-
cipate, systematic analysis of data to identify potential
sex-based differences is lacking. Similarly, editorial poli-
cies in scientific journals requiring or encouraging gen-
der analysis in reported research are more often the
exception than the rule.
Standards for reporting of clinical trials have been
established to ensure provision of complete and trans-
parent critical information. The Consolidated Standards
of Reporting Trials (CONSORT) group came together
in 1996 to provide uniform guidelines for accurate and
adequate reporting of randomized clinical trials. Despite
two revisions of the guidelines since its conception, the
CONSORT statement fails to make any mention of sex
and gender. Since the 2010 statement indicates that an
aspiration of the group is to help improve design, con-
duct and reporting of trials, an important step in
addressing the gender imbalance would be inclusion of
a gender perspective in the next CONSORT guideline
revision [7,8]. Others including UNAIDS have also
requested such an inclusion in the CONSORT state-
ment revision [8].
The International Committee of Medical Journal Edi-
tors (ICMJE) defines standards for scientific reporting in
its Uniform Requirements for Manuscripts Submitted to
Biomedical Journals [9]. Fortunately, these do propose
analyses of data by such variables as age and sex “where
scientifically appropriate”; this is an encouraging sugges-
tion as the Uniform Requirements are a well-recognized
and widely used set of guidelines for authors and biome-
dical journals. However, systematic provision of data
disaggregated by sex (and age) is not only desirable, but
should also be strongly recommended. ICMJE is cer-
tainly in a position to emphasize the ethical obligation
of authors to present data analyzed by sex as a matter
of routine.
Lately, there have been some positive developments
on gender inclusion in medical research, and a growing
number of efforts recognize the gender gap in science.
A recent European gender summit co-organized by
GenSET network and the European Science Foundation
and supported by the European Commission may be
one of the most comprehensive gatherings to review
gender inequality and its consequences for science to
date [10,11]. Presentations at the meeting highlighted
how gender inequity becomes more pronounced as one
ascends the academic career ladder, and how research
falls short of ensuring that findings are relevant for sub-
populations and will benefit both women and men. Data
were also presented on how gender diversification posi-
tively stimulates innovation and productivity. The out-
come of the summit was a manifesto signed by, among
others, several science editors. The manifesto underlines
that “the assertion that science is gender neutral is not
the case”, and calls for researchers, funding bodies,
reviewers and journal editors to consider gender in
research design, conduct and reporting [12].
The Lancet took a positive step following the gender
summit in November 2011, when its editors introduced
a very welcome policy, encouraging inclusion of sex and
gender analysis in submitted manuscripts [13]. The Jour-
nal of the International AIDS Society also has a policy to
this effect [14]. Our aspiration is that a similar policy be
adopted across all scientific journals. Most importantly,
however, we call on the ICMJE and CONSORT groups
to recognize the importance of systematic analysis and
reporting of sex differences from trials and to ensure
that their guidelines introduce gender dimensions in
their checklists and flowcharts, and recommend inclu-
sion of this parameter as a matter of routine in the
reporting of clinical data on human subjects.
Editors are often referred to as the gatekeepers of
science, responsible for ensuring that what is published
in scientific journals qualifies, both scientifically and
ethically, as contributions to the collective pool of
knowledge. Editors are also promoters of ethical
research and adequate standards of reporting. Require-
ments for inclusion of gender analyses should not go
unnoticed.
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